Digital Desk, New Delhi. The Drug Controller General of India (DCGI) has given approval to Serum Institute of India to manufacture the Sputnik V vaccine. Serum Institute had applied for test, analysis and examination to DCGI on Wednesday. DGCA has given this approval to Serum Institute at their licensing facility at Hadapsar, Pune, subject to certain conditions. Currently, Sputnik-V is also being manufactured in India by Dr Reddy’s Laboratories.
The Pune-based company has collaborated with Gamalya Research Institute of Epidemiology and Microbiology, Moscow in Russia to develop Sputnik V in India.
Russia’s Sputnik V was approved for emergency use by DCGI in April. SII is the sixth pharmaceutical company after Hetero Biopharma, Gland Pharma, Panacea Biotec, Stelis Biopharma and Virchow Biotech to manufacture Sputnik V in India. Meanwhile, Hyderabad-based Dr Reddy’s Laboratories has tied up with Russian Direct Investment Fund to sell the first 250 million imported voids of Sputnik V in India.
The imported dosages are priced at Rs 995.40 per dose and Dr Reddy’s has indicated that the prices will come down once the local supply resumes. The first consignment of Sputnik vaccines made in India got clearance from Central Drug Laboratory, Kasauli on Tuesday. Sputnik is now registered in more than 50 countries. According to a study, the efficacy of this vaccine (both doses) is 97.6 percent.